What it's for (Indications)
- Olmesartan medoxomil + hydrochlorothiazide is indicated for the treatment of essential hypertension in adult patients whose blood pressure is not adequately controlled with monotherapy.
- This fixed-dose combination offers a comprehensive approach to blood pressure reduction by targeting multiple physiological pathways involved in hypertension.
- The decision to use a combination therapy should be individualized, based on the patient's existing antihypertensive regimen, blood pressure response, and tolerability.
- It is not indicated for initial therapy in patients with mild hypertension, but rather for those requiring more aggressive blood pressure control or who have not achieved their target blood pressure with either olmesartan or hydrochlorothiazide alone.
- Regular blood pressure monitoring is crucial to assess the efficacy of the treatment and ensure target blood pressure goals are met to mitigate risks of cardiovascular events.
- Its use should be part of a comprehensive cardiovascular risk reduction strategy.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of olmesartan medoxomil + hydrochlorothiazide should be individualized based on the patient's blood pressure response and tolerability, and it is generally administered orally once daily with or without food. Available strengths include various combinations, such as olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg, and olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg or 25 mg. Patients whose blood pressure is not adequately controlled with olmesartan monotherapy may be started on the combination. If blood pressure remains uncontrolled after 2-4 weeks of treatment, the dose may be increased, or the patient may be switched to a higher strength combination, up to the maximum recommended daily dose. For patients with renal impairment, dose adjustment and careful monitoring of renal function and serum electrolytes are recommended, as the diuretic component can exacerbate renal dysfunction and necessitate careful consideration of the combination's appropriateness. It is not recommended as initial therapy for patients requiring aggressive blood pressure control. |
Safety & Warnings
Common Side Effects
- Common side effects associated with olmesartan medoxomil + hydrochlorothiazide include dizziness, headache, fatigue, and nasopharyngitis.
- Due to the hydrochlorothiazide component, patients may experience electrolyte disturbances such as hypokalemia, hyponatremia, hypomagnesemia, and hypochloremic alkalosis.
- Hyperuricemia and hyperglycemia are also potential metabolic effects of thiazide diuretics.
- Less common but serious adverse effects include symptomatic hypotension, particularly in volume-depleted patients, and acute kidney injury, which may be exacerbated in patients with pre-existing renal impairment or heart failure.
- Rarely, olmesartan can cause sprue-like enteropathy with severe, chronic diarrhea and substantial weight loss, which may manifest months to years after initiation.
- Hydrochlorothiazide has been associated with acute transient myopia and acute angle-closure glaucoma, requiring immediate discontinuation.
- Angioedema, though rare, is a potentially life-threatening reaction to ARBs.
- Photosensitivity reactions can also occur, and systemic lupus erythematosus may be exacerbated.
Serious Warnings
- Black Box Warning: **WARNING: FETAL TOXICITY** Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. When pregnancy is detected, olmesartan medoxomil + hydrochlorothiazide should be discontinued as soon as possible. There is a critical period of susceptibility to ARB-induced fetal toxicity during the second and third trimesters of pregnancy. Exposure to olmesartan during these trimesters has been shown to cause fetal injury including hypotension, renal failure, oligohydramnios, skull hypoplasia, anuria, and death. Oligohydramnios, resulting from decreased fetal renal function, can be associated with fetal lung hypoplasia and skeletal deformations. Neonates with a history of in utero exposure to ARBs should be closely observed for hypotension, oliguria, and hyperkalemia. If oliguria occurs, attention should be directed toward support of blood pressure and renal perfusion. Exchange transfusion or dialysis may be required as a means of reversing hypotension and/or substituting for impaired renal function. These adverse effects are not typically seen with first trimester exposure, but discontinuation should still occur immediately upon detection of pregnancy to minimize potential risks to the fetus and newborn.
- Several important warnings and precautions are associated with the use of olmesartan medoxomil + hydrochlorothiazide.
- Symptomatic hypotension may occur, especially in patients who are volume-depleted (e.
- g.
- , those on high-dose diuretics) or salt-depleted; careful monitoring and correction of volume/salt depletion prior to initiation is crucial.
- Dual blockade of the renin-angiotensin-aldosterone system (RAAS) with an ARB, ACE inhibitor, or aliskiren is not recommended, particularly in patients with diabetes or renal impairment, due to an increased risk of hypotension, hyperkalemia, and renal function deterioration.
- Renal function should be monitored periodically, especially in patients with pre-existing renal impairment or heart failure, as ARBs can cause azotemia.
- Electrolyte imbalances, including hypokalemia, hyponatremia, hypercalcemia, and hypomagnesemia, can occur due to the diuretic component, necessitating regular monitoring.
- Acute angle-closure glaucoma, characterized by acute onset of decreased visual acuity or ocular pain, has been reported with hydrochlorothiazide and requires immediate medical attention.
- Patients with severe symptomatic chronic diarrhea and substantial weight loss developing months to years after drug initiation should be evaluated for sprue-like enteropathy caused by olmesartan, and the drug should be discontinued if confirmed.
- Hepatic impairment also requires caution, as olmesartan exposure may increase.
How it Works (Mechanism of Action)
Olmesartan medoxomil + hydrochlorothiazide exerts its antihypertensive effects through a complementary dual mechanism. Olmesartan medoxomil is a prodrug that is rapidly converted to its active metabolite, olmesartan. Olmesartan acts as a selective AT1 subtype angiotensin II receptor antagonist. By blocking the binding of angiotensin II to the AT1 receptor, it inhibits the potent vasoconstrictor and aldosterone-secreting effects of angiotensin II. This leads to peripheral vasodilation, decreased systemic vascular resistance, and reduced sodium and water reabsorption in the kidneys, ultimately lowering blood pressure. Hydrochlorothiazide is a thiazide diuretic that primarily acts in the cortical diluting segment of the distal convoluted tubule. It inhibits the active reabsorption of sodium and chloride ions from the luminal membrane via the Na+-Cl- cotransporter, increasing the excretion of sodium, chloride, and water. This diuretic effect reduces plasma volume, cardiac output, and consequently, blood pressure. The combination provides additive blood pressure lowering by addressing both RAAS overactivity and volume expansion, offering a more robust antihypertensive effect than either component alone.